Worrying results from genotyping quality assessments

Focus on screening, not biomarkers

Inequalities in immuno-oncology access across Europe

Measuring innovation and value in healthcare systems

Could personalised medicine increase inequality to medicine access?

The economics of personalised medicine in low and middle income countries

Creating a culture of shared data

Accelerating research to the bedside

Developing drugs for personalised medicine

Next generation sequencing identifies smoldering multiple myeloma patients with a high risk of disease progression

The Innovative Medicines Initiative

Daratumumab for patients with multiple myeloma